TP53 and ovarian carcinoma: Therefore, our study uncovers an important dual role of the UPR network in response to AZD1775 treatment in TP53‐mutated ovarian cancer, and provide a rationale for targeting the IRE1α‐XBP1s axis to enhance the efficacy of AZD1775.